A Special Investigation Team (SIT) has been established to investigate the tragic toxic cough syrup deaths of 14 children in Chhindwara, Madhya Pradesh. Authorities suspect renal failure, linking these fatalities directly to the consumption of a contaminated cough syrup. Consequently, a doctor faces arrest, and the manufacturer of the implicated ‘Coldrif’ cough syrup has also been booked.
Toxic Cough Syrup Deaths Prompt SIT Formation
Madhya Pradesh police swiftly formed a 12-member SIT to probe the deaths of 14 children in Chhindwara. The team, led by Parasia Sub Divisional Officer of Police Jitendra Singh Jat, will notably visit the pharma company in Tamil Nadu. Officials linked these fatalities to suspected renal failure after children consumed a toxic cough syrup. Furthermore, Dr. Praveen Soni from Chhindwara has been arrested for alleged negligence concerning these child deaths. Meanwhile, a case has been registered against Sresan Pharmaceutical, the manufacturer of the Coldrif cough syrup. Initial reports confirmed that the Coldrif syrup contained diethylene glycol (DEG), a poisonous substance.
The state government announced an ex gratia payment of Rs 4 lakh for each victim’s family, transferring these funds directly to their bank accounts. In fact, the body of two-year-old Yogita Thakre, the last victim, was exhumed for post-mortem at her family’s request. Eight children are currently receiving treatment in Nagpur, with four in government hospitals, one at AIIMS, and three in private facilities. Additionally, two children in MP’s Betul district also died, allegedly after taking the same Coldrif cough syrup.
Contaminated Coldrif Syrup: A Public Health Crisis
The Madhya Pradesh government has banned the sale of Coldrif cough syrup, manufactured by Sresan Pharmaceutical in Kancheepuram, Tamil Nadu. Officials reported that drug samples contained a highly toxic substance, specifically diethylene glycol (DEG) at 48.6% w/v. This toxic substance is known to render the contents injurious to health. Consequently, the Tamil Nadu drug control authorities declared the Coldrif syrup sample (Batch No SR-13; Mfg: May 2025; Exp: April 2027) as adulterated on October 2. Following this critical report, the Madhya Pradesh Food and Drug Administration instructed a statewide halt to sales and distribution of Coldrif. They also ordered the immediate seizure of all available stock for investigation under the Drugs and Cosmetics Act, 1940. Moreover, other products manufactured by Sresan Pharmaceuticals are to be removed from sale pending further testing.
Of the children who died, 11 were from Parasia sub-division, two from Chhindwara city, and one from Chaurai tehsil. Samples from affected children have been sent to the National Institute of Virology in Pune for further analysis. Furthermore, additional tests on the syrup’s adulteration and contamination are ongoing.
Legal Action and Wider Repercussions
Dr. Soni and Sresan Pharmaceutical face charges under various sections of the Bharatiya Nyaya Sanhita, including 105 (culpable homicide not amounting to murder) and 276 (adulteration of drugs). They have also been booked under Section 27A of the Drugs and Cosmetics Act, which can lead to over 10 years’ imprisonment or a life term. The government suspended Dr. Soni from service after Chief Minister Mohan Yadav pledged strict action against those responsible.
However, the medical community has reacted strongly to Dr. Soni’s arrest. His colleagues, particularly from the Indian Medical Association, have threatened an indefinite strike from Monday if he is not released. They argue he was practicing at a private clinic and prescribed the syrup, but the primary fault lies with the manufacturing. The Opposition Congress has also announced protests from Monday. They aim to highlight the perceived failure of the BJP government in managing the crisis and demand increased financial relief for the affected families.
The Central Drugs Standard Control Organisation (CDSCO) has initiated risk-based inspections at 19 drug manufacturing units across six states. These inspections include manufacturers of cough syrups and antibiotics, signaling a broader regulatory crackdown to prevent future such tragedies.
Frequently Asked Questions
Q1: What caused the deaths of the children in Madhya Pradesh?
The deaths of 14 children in Madhya Pradesh are linked to renal failure after consuming Coldrif cough syrup, which was found to be contaminated with a high concentration of diethylene glycol (DEG), a toxic substance.
Q2: What actions have been taken against the responsible parties?
A doctor who prescribed the syrup has been arrested and suspended. Additionally, a case has been registered against Sresan Pharmaceutical, the manufacturer of Coldrif, under charges including culpable homicide and drug adulteration. The state government has also banned the syrup’s sale.
Q3: Is the Coldrif cough syrup available for sale in other regions?
Following the deaths and contamination reports, the Madhya Pradesh government has banned the sale of Coldrif cough syrup statewide. Furthermore, Tamil Nadu and Maharashtra have also banned the product, and other states have issued alerts and initiated actions to remove the syrup from circulation.
References
- SIT to probe death of 14 children in MP; Doctor held, ‘toxic’ cough syrup maker booked – ETHealthworld
- India probes possible cough syrup link to deaths of at least nine children – Al Jazeera
- Indian health ministry confirms presence of diethylene glycol beyond permissible limits in Coldrif cough syrup – Xinhua
- Coldrif tragedy: Doctor held, SIT set up as Madhya Pradesh’s ‘syrup toll’ rises to 14
- Cough Syrup, Then More Sickness And Death: Shell-Shocked Families Try To Cope – NDTV
- Six children die in Chhindwara as toxic cough syrup triggers kidney failure – Newsonair
- Doctor arrested after 16 children die in Madhya Pradesh from toxic cough syrup
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.